Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2024 | $17.00 | Outperform | Wolfe Research |
| 1/5/2024 | $20.00 | Overweight | Piper Sandler |
| 12/12/2023 | $14.00 | Buy | Deutsche Bank |
| 10/17/2023 | $17.00 | Buy | Guggenheim |
| 6/8/2023 | $10.50 | Neutral | BofA Securities |
| 10/27/2022 | $7.00 | Overweight | JP Morgan |
| 5/23/2022 | $6.00 | Outperform | SVB Leerink |
| 4/29/2022 | $15.00 | Overweight | Cantor Fitzgerald |
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
4 - Roivant Sciences Ltd. (0001635088) (Issuer)
BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year; first patients enrolled in Phase 3 NIU program IMVT-1402 cleared five Investigational New Drug (IND) applications across a range of therapeutic areas and FDA divisions, including the potentially registrational trial for difficult-to-treat rheumatoid arthritis (D2T RA) expected to initiate by March 31, 2025Batoclimab pro
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call
Mosliciguat, a potential first-in-class and best-in-category inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, is being developed for pulmonary hypertension associated with interstitial lung disease (PH-ILD), which affects ~200,000 patients in the U.S. and Europe; PH-ILD prevalence is meaningfully greater than that of pulmonary arterial hypertension (PAH) with limited to no treatment optionsIn the Phase 1b ATMOS study, presented today at the European Respiratory Society (ERS) Congress, a single dose of inhaled mosliciguat in pulmonary hypertension (PH) patients (N=38) led to sustained, clinically meaningful mean-max reduction
Piper Sandler analyst Allison Bratzel maintains Roivant Sciences (NASDAQ:ROIV) with a Overweight and raises the price target from $20 to $22.
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 0 0 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 4 0 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.33, a high estimate of $23.00, and a l
Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.
Wolfe Research initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $17.00
Piper Sandler initiated coverage of Roivant Sciences with a rating of Overweight and set a new price target of $20.00
Deutsche Bank initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $14.00
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
8-K - Roivant Sciences Ltd. (0001635088) (Filer)
144 - Roivant Sciences Ltd. (0001635088) (Subject)
NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T
BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year; first patients enrolled in Phase 3 NIU program IMVT-1402 cleared five Investigational New Drug (IND) applications across a range of therapeutic areas and FDA divisions, including the potentially registrational trial for difficult-to-treat rheumatoid arthritis (D2T RA) expected to initiate by March 31, 2025Batoclimab pro
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant's website after the conference call
BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE:OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ:ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-dermatology. Please see our prior announcement for a summary of the transaction terms. VTAMA® (tapinarof) cream, 1%, is a novel nonbiologic, non-steroidal topical therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of mild, moderate, and severe plaq